Login to Your Account

Otonomy Averts disaster in Ménière's, phase III win happy surprise

By Randy Osborne
Staff Writer

Thursday, November 9, 2017

Otonomy Inc. CEO David Weber told BioWorld that researchers at his firm "have what we need to continue moving forward" in Ménière's disease with Otividex, the sustained-exposure formulation of dexamethasone that cheered investors by ringing the phase III bell after a similar late-stage experiment failed.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription